Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma

Current treatment for patients with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy (nCT), alone or combined with radiotherapy, before surgery. However, fewer than 30% of treated patients show a pathologic complete response to nCT, which correlates with increased 5-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbore, Giuseppina, Albarello, Luca, Bucci, Gabriele, Punta, Marco, Cossu, Andrea, Fanti, Lorella, Maurizio, Aurora, Di Mauro, Francesco, Bilello, Vito, Arrigoni, Gianluigi, Bonfiglio, Silvia, Biancolini, Donatella, Puccetti, Francesco, Elmore, Ugo, Vago, Luca, Cascinu, Stefano, Tonon, Giovanni, Rosati, Riccardo, Casorati, Giulia, Dellabona, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Cancer Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472105/
https://www.ncbi.nlm.nih.gov/pubmed/37350667
http://dx.doi.org/10.1158/0008-5472.CAN-23-0356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472105/
https://www.ncbi.nlm.nih.gov/pubmed/37350667
http://dx.doi.org/10.1158/0008-5472.CAN-23-0356

Ejemplares similares